According to EurekaAlert, Novo Biosciences Inc., a spinoff of the MDI Biological Laboratory in Bar Harbor, Maine, has announced that it has received a two-year, $1.5 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for the development of MSI-1436 as a potential regenerative medicine therapy for the treatment of patients who have suffered an acute heart attack. “We believe MSI-1436 has enormous potential,” said Kevin Strange, Ph.D., CEO of Novo Biosciences and president of the MDI Biological Laboratory. “No drug now exists to treat heart attack. Heart disease is the the world’s leading killer. In order to advance MSI-1436 into clinical trials, we need to first test its effectiveness in a large animal model. We are deeply grateful to the National Heart, Lung, and Blood Institute for making this possible.” Read more
Novo Biosciences Receives Federal Grant to Advance Potential Heart Drug
Related Posts
Bar Harbor approves Jackson Lab’s $33M expansion for rare disease research
The Bar Harbor Planning Board has approved a plan by the Jackson Laboratory to build a 20,000-square-foot expansion to its Rare Disease Translational...
Bigelow lab receives $7 million for algae research, business development
Researchers at Bigelow Laboratory for Ocean Sciences believe algae can make a big splash in the agricultural, aquaculture and pharmaceutical industries,...
Should Maine create a public medical school? UMaine System will study the question
The University of Maine System said this week it will work with a national consultant to study the feasibility of launching the state’s...